Gabapentin
Gabapentin has been studied in 49 papers since 2016: 17 observational studies in people, 5 in animals, 1 in cells, 25 reviews; 23 in the past year. It is an approved medicine. The newest paper, Nov 18, 2026: “Non-hormonal management of menopause symptoms—the statement of the European Society of Gynecology”.
6 new papers in 30 daysSee all 56 papers on gabapentin
At a glance
The findings reach people, from one lab or study. 6 independent labs in 3 countries; 208 trials, 5 about aging, 87 with no results posted.
“No difference in mortality was observed between groups (adjusted hazard ratio and 95% confidence interval for gabapentin + opioids 0.98 [0.90-1.06]; P = 0.63).”
1 of its findings points the other way.
- 6 independent labs in 3 countries
- 1 finding against
- 208 trials, 5 about aging, 87 with no results posted
- Funders: National Institutes of Health and 6 more
- 18 of 208 trials sponsored by its developers
- Humans17
- Animals4
- Model organisms1
- Cells1
What did studies of gabapentin find?
10Studies of gabapentin measured 10 outcomes, among them mortality, vasomotor symptoms and hot flashes.
Mortality
no changein humans2HR 0.98
2 studies
Mortality
no changein humans2HR 0.98
Gabapentin was not clearly linked with mortality in humans (spine-related diagnoses, taking opioids, compared to TCAs/duloxetine + opioids) (aHR 0.98 (95% CI 0.90-1.06), P = 0.63).
“No difference in mortality was observed between groups (adjusted hazard ratio and 95% confidence interval for gabapentin + opioids 0.98 [0.90-1.06]; P = 0.63).”
Humansspine-related diagnoses, taking opioids, compared to TCAs/duloxetine + opioidsfemale 66.7%sn = 134,266
Pain
Gabapentin was not clearly linked with mortality in humans (concurrent opioid treatment in people with spine diagnoses) (adjusted HR 0.98 (0.90, 1.06)).
“No difference in mortality was observed between groups (adjusted hazard ratio (HR) and 95% confidence interval (CI) for gabapentin + opioids was 0.98 (0.90, 1.06); p=0.63).”
Humansconcurrent opioid treatment in people with spine diagnosesmedian 45 days66.7% femalesn = 134,266
medRxiv : the preprint server for health sciencesPreprint
Vasomotor symptoms
downin humans1
1 study
Vasomotor symptoms
downin humans1
Gabapentin decreases vasomotor symptoms in humans (for vasomotor symptoms in patients with cancer).
“strong evidence supporting selective serotonin and norepinephrine reuptake inhibitors, gabapentin, and lifestyle interventions for vasomotor symptoms”
Reviewfor vasomotor symptoms in patients with cancer
Menopause Management in Patients With Cancer
Obstetrics and gynecology
Hot flashes
downin humans1
1 study
Hot flashes
downin humans1
Gabapentin decreases hot flashes in humans (breast cancer patients receiving endocrine therapy) (25–69% reduction).
“Pharmacological options, including SSRIs (e.g., paroxetine, escitalopram), SNRIs (e.g., venlafaxine, desvenlafaxine), and gabapentin, have shown more consistent reductions in hot flash frequency and severity (25–69%)”
Reviewbreast cancer patients receiving endocrine therapy
Non-hormonal treatments for hot flashes in breast cancer patients: a narrative review
Future Journal of Pharmaceutical Sciences
tau phosphorylation
upin mice1
1 study
tau phosphorylation
upin mice1
Gabapentin increases tau phosphorylation in mice.
“In the hippocampus of GBP-treated mice, increased levels of p-tau (S416) and p-tau (S262) were observed”
Animalshippocampus60 daysfemales
Long-term gabapentin treatment impairs cognitive function in aged mice via tau hyperphosphorylation
Frontiers in pharmacology
Learning and memory
downin mice1
1 study
Learning and memory
downin mice1
Gabapentin impairs learning and memory in mice with or without nerve injury-induced pain.
“Long-term GBP treatment impaired learning and memory in aged mice with or without nerve injury-induced pain”
Animalswith or without nerve injury-induced pain60 daysfemales
Long-term gabapentin treatment impairs cognitive function in aged mice via tau hyperphosphorylation
Frontiers in pharmacology
Vasomotor symptoms
downin humans1
1 study
Vasomotor symptoms
downin humans1
Gabapentin decreases vasomotor symptoms in humans (menopause).
“Gabapentin, and Pregabalin are effective for managing vasomotor symptoms as well as other menopausal symptoms.”
Reviewmenopausefemales
Non-oestrogen-based and complementary therapies for menopause
Best practice & research. Clinical endocrinology & metabolism
Fragility fracture
no changein humans1HR 1.02
1 study
Fragility fracture
no changein humans1HR 1.02
Gabapentin was not clearly linked with fragility fracture in humans (Gabapentin initiation compared with pregabalin initiation) (HR 1.02 (95% CI 0.86–1.21) versus pregabalin).
“short-term risk of fragility fractures among gabapentin initiators was not different compared to those initiating pregabalin.”
HumansGabapentin initiation compared with pregabalin initiation90 days
Basic & clinical pharmacology & toxicology
Physical function
downin humans1OR 1.78
1 study
Physical function
downin humans1OR 1.78
Gabapentin is linked with worse physical function in humans (initially normal cognition) (OR 1.78, 95% CI 1.12–2.83).
“and mean of FAQ at index+2 visit (1.78 [1.12, 2.83]).”
Humansinitially normal cognition
Frontiers in pharmacology
Cognitive function
downin humans1OR 1.55
1 study
Cognitive function
downin humans1OR 1.55
Gabapentin is linked with worse cognitive function in humans (initially normal cognition) (OR 1.55, 95% CI 1.07–2.25).
“Gabapentin initiation was significantly associated with cognitive/functional status decline: worsening CDRGLOB at index+1 visit (odds ratio [95% confidence interval]: 1.55 [1.07, 2.25])”
Humansinitially normal cognition
Frontiers in pharmacology
Motor function
upin flies1
1 study
Motor function
upin flies1
Gabapentin improves motor function in hFUS-Q290X transgenic flies.
“The involvement of the GABAergic pathway was supported by rescue of motor symptoms with gabapentin.”
Model organismsin hFUS-Q290X transgenic flies
FUS-linked essential tremor associated with motor dysfunction in Drosophila
Human genetics
What is gabapentin linked with?
4Studies link gabapentin with 4 measures, among them dementia, major medical complication and falls.
Dementia
upin humans2no changein humans1HR 1.09–7.39
2 studies
Dementia
upin humans2no changein humans1HR 1.09–7.39
Gabapentin is associated with dementia in patients without CKD (HR 1.09; 95% CI, 0.89-1.34).
“versus a near-null association in patients without CKD (HR 1.09; 95% CI, 0.89-1.34; P=0.41)”
Humansin patients without CKD
medRxiv : the preprint server for health sciencesPreprint
Gabapentin is linked with a higher risk of dementia in patients with CKD (HR 7.39; 95% CI, 3.43-15.92).
“gabapentin was associated with substantially elevated dementia risk in patients with CKD (hazard ratio [HR] 7.39; 95% CI, 3.43-15.92; P<0.001)”
Humansin patients with CKD
medRxiv : the preprint server for health sciencesPreprint
Gabapentin is linked with a higher risk of dementia in humans among patients also taking a CCB (vs pregabalin) (time-varying HR, 1.52 [95% CI, 1.23–1.89]).
“gabapentin initiation was associated with higher dementia incidence among patients also taking a CCB than among those not taking a CCB (time-varying HR, 1.52 [95% CI, 1.23–1.89]”
Humansamong patients also taking a CCB (vs pregabalin)n = 33,791
medRxivPreprint
Major medical complication
upin humans2HR 1.02
2 studies
Major medical complication
upin humans2HR 1.02
Gabapentin is linked with a higher risk of major medical complication in humans (spine-related diagnoses, taking opioids, compared to TCAs/duloxetine + opioids) (aHR 1.02 (95% CI 1.00-1.04), P = 0.03).
“people treated with gabapentin + opioids were at slightly increased risk of a major medical complication (1.02 [1.00-1.04]; P = 0.03)”
Humansspine-related diagnoses, taking opioids, compared to TCAs/duloxetine + opioidsfemale 66.7%sn = 134,266
Pain
Gabapentin is linked with a higher risk of major medical complication in humans (concurrent opioid treatment in people with spine diagnoses) (adjusted HR 1.02 (1.00, 1.04)).
“people treated with gabapentin + opioids were at slightly increased risk of a major medical complication (1.02 (1.00, 1.04); p=0.03) compared to those treated with TCAs/duloxetine + opioids.”
Humansconcurrent opioid treatment in people with spine diagnosesmedian 45 days66.7% femalesn = 134,266
medRxiv : the preprint server for health sciencesPreprint
Falls
upin humans2OR 2.5–2.51
2 studies
Falls
upin humans2OR 2.5–2.51
Gabapentin is associated with falls in humans (older adults with cognitive impairment) (OR 2.5, 95% CI 1.3-4.6).
“gabapentin initiation was significantly associated with increased odds of new falls at the index + 2 visit (odds ratio [95% confidence interval] 2.5 [1.3, 4.6]).”
Humansolder adults with cognitive impairment2 years (index + 2 visit)
Drugs & aging
Gabapentin is linked with a higher risk of falls in humans (initially normal cognition, excluding extant motor dysfunction) (OR 2.51, 95% CI 1.19–5.31).
“in this sample, gabapentin initiation was associated with increased falls at the index+2 visit (2.51 [1.19, 5.31]).”
Humansinitially normal cognition, excluding extant motor dysfunction
Frontiers in pharmacology
Incident dementia
upin humans1HR 2.44
1 study
Incident dementia
upin humans1HR 2.44
Gabapentin is associated with incident dementia in humans (IPTW HR 2.44, 95% CI 1.06–5.63, p=0.036).
“When gabapentin was added to a regimen that already included a DHP-CCB, incident dementia risk was elevated relative to pregabalin”
HumansHypertension; gabapentin added after prior dihydropyridine calcium channel blocker therapy, compared with pregabalinn = 7,141
medRxivPreprint
Has gabapentin been tested in people?
5 of 208 about agingYes: 17 observational studies in people have been published, and 207 trials are registered.
About aging
Phase 3Completed
Phase 3Completed
Phase 2Completed
The Menopause After Cancer Study
Phase 2Completed
Phase 3Completed
Approved
Dec 30, 1993Epilepsy, Neuralgia, Postherpetic, Seizures
Oct 9, 1998Epilepsy, Neuralgia, Postherpetic, Seizures
Mar 2, 2000Epilepsy, Neuralgia, Postherpetic, Seizures
Oct 12, 2000
May 24, 2002
May 24, 2002
All 8Fewer
Repurposing
Phase 4Completed1 trial
Phase 3Terminated1 trial
Phase 3Results posted1 trial
Phase 3Terminated2 trials
Phase 4Results posted17 trials
Phase 3Results posted1 trial
40 of 109Fewer
Every condition in trials
Abuse potential
Phase 4Results posted2 trials
Cardiopulmonary bypass
Phase 4Completed1 trial
Sleep
Phase 4Terminated1 trial
Squamous cell carcinoma of head and neck
Phase 3Recruiting2 trials
Alcohol drinking
Phase 3Completed1 trial
Pathologic processes
Phase 3Completed1 trial
All 13Fewer
Readouts due
- Jan 1, 2027
- Jun 2027
Enhanced Recovery After Surgery (ERAS) in Live Donor Kidney Transplant Recipients
Phase 4Enrolling by invitation
- Sep 2027
Stopped
NCT00236223TerminatedPostoperative pain
Structural changes that stopped the type of operations used in the study
NCT05024825TerminatedPostoperative pain
recruitment target not met.
NCT02771925TerminatedAlcoholism
Due to poor compliance of patients in the study.
NCT00584779TerminatedRenal insufficiency
See detailed description for termination reason
NCT00785772TerminatedRenal insufficiency
See termination reason in detailed description.
NCT02599701TerminatedSleep
Gabapentin increased hypopnea-apnea index in the first 8 recruited subjects.
All 15Fewer
Who is developing gabapentin?
2 companies: Endo USA Inc., a Keenova Therapeutics Company and Dompé Farmaceutici S.p.A.
Trial sponsors
Company16 trialsPhase 46,335 people
Company2 trialsPhase 4457 people
Company2 trialsPhase 4106 people
Company1 trialPhase 4407 people
Company1 trialPhase 462 people
Company6 trialsPhase 32,683 people
Pharmaceutical Research Management
Company1 trialPhase 32 people
Company1 trialPhase 2378 people
Funding
2 grants since 2023National Institute on Aging$429K